iScience
Volume 26, Issue 4, 21 April 2023, 106413
Journal home page for iScience

Article
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

https://doi.org/10.1016/j.isci.2023.106413Get rights and content
Under a Creative Commons license
open access

Highlights

  • SARS-CoV-2 variants have increased with the concomitant rise of many subvariants

  • Sotrovimab retains some activity against BQ.1, BQ.1.1 and XBB

  • The Evusheld/AZD7442 cocktail lost all activity against all subvariants tested

  • Bebtelovimab lost all neutralizing activity against BQ.1, BQ.1.1, and XBB variants

Summary

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous appearance of multiple subvariants originating from BA.2, BA.4, and BA.5 Omicron sub-lineages. They harbor a specific set of mutations in the spike that can make them more evasive to therapeutic monoclonal antibodies. In this study, we compared the neutralizing potential of monoclonal antibodies against the Omicron BA.2.75.2, BQ.1, BQ.1.1, and XBB variants, with a pre-Omicron Delta variant as a reference. Sotrovimab retains some activity against BA.2.75.2, BQ.1, and XBB as it did against BA.2/BA.5, but is less active against BQ.1.1. Within the Evusheld/AZD7442 cocktail, Cilgavimab lost all activity against all subvariants studied, resulting in loss of Evusheld activity. Finally, Bebtelovimab, while still active against BA.2.75, also lost all neutralizing activity against BQ.1, BQ.1.1, and XBB variants.

Subject areas

Components of the immune system
Virology
Biochemical analysis

Data and code availability

  • This study did not generate/analyze any datasets.

  • This study did not generate/analyze any code.

Cited by (0)

5

These authors contributed equally

6

Senior author

7

Lead contact